▁British 10.375
▁Bi 10.875
ote 5.59765625
ch 4.53515625
' 7.3671875
s 1.04296875
▁Can 5.2890625
cer 1.43359375
▁D 4.6640625
rug 3.82421875
▁Sh 8.015625
ows 3.69140625
▁Promise 10.1171875
, 6.4375
▁But 4.66015625
▁Anal 9.8984375
yst 2.826171875
s 2.037109375
▁Ur 8.7734375
ge 2.001953125
▁Ca 6.953125
ution 0.26123046875
<0x0A> 4.74609375
In 4.46875
▁a 2.580078125
▁land 5.60546875
mark 0.0203094482421875
▁development 4.015625
▁in 1.5576171875
▁the 0.79736328125
▁field 2.025390625
▁of 0.052764892578125
▁cancer 2.853515625
▁treatment 2.314453125
, 0.145263671875
▁British 5.47265625
▁bi 3.94140625
ote 0.11328125
chn 1.439453125
ology 0.046478271484375
▁company 0.578125
, 2.25390625
▁Bi 4.59765625
ote 0.7236328125
ch 0.7783203125
▁UK 5.015625
, 0.85498046875
▁has 0.71337890625
▁revealed 4.48046875
▁prom 6.09375
ising 0.0031719207763671875
▁results 0.76904296875
▁in 2.38671875
▁the 1.310546875
▁early 3.47265625
▁stages 1.4990234375
▁of 0.023284912109375
▁testing 2.822265625
▁for 2.7421875
▁their 3.234375
▁innov 3.951171875
ative 0.043609619140625
▁cancer 1.708984375
▁drug 1.759765625
. 1.380859375
▁While 6.17578125
▁this 3.091796875
▁news 3.794921875
▁has 2.43359375
▁spark 4.546875
ed 0.002941131591796875
▁hope 2.607421875
▁among 2.064453125
▁patients 1.9970703125
▁and 1.2509765625
▁medical 2.595703125
▁profession 0.42626953125
als 0.003505706787109375
▁al 1.0439453125
ike 4.410743713378906e-05
, 0.10125732421875
▁industry 6.625
▁anal 2.34375
yst 0.0017786026000976562
s 0.01328277587890625
▁are 1.6240234375
▁ur 3.814453125
ging 0.00823974609375
▁ca 0.043426513671875
ution 0.00019299983978271484
▁as 2.81640625
▁the 1.1982421875
▁drug 1.78125
' 2.5234375
s 0.00031495094299316406
▁potential 2.841796875
▁benefits 3.291015625
▁must 3.697265625
▁be 0.274658203125
▁bal 3.091796875
anced 0.0007853507995605469
▁with 1.12109375
▁a 4.03125
▁thorough 7.01953125
▁evaluation 2.875
▁of 0.085693359375
▁its 0.8525390625
▁safety 2.83203125
▁and 0.623046875
▁effic 0.91650390625
acy 0.0002665519714355469
. 0.285888671875
<0x0A> 0.1707763671875
The 1.8173828125
▁experimental 5.58203125
▁drug 0.346435546875
, 0.431396484375
▁currently 5.56640625
▁named 3.767578125
▁B 2.689453125
TX 3.927734375
- 0.186279296875
1 2.826171875
2 2.25390625
3 2.486328125
, 0.5478515625
▁targets 3.728515625
▁cancer 3.158203125
▁cells 0.49267578125
▁using 3.560546875
▁a 0.6259765625
▁novel 2.69140625
▁mechanism 2.427734375
▁that 1.830078125
▁promises 7.47265625
▁both 6.00390625
▁increased 3.83984375
▁effect 1.8408203125
iveness 0.00551605224609375
▁and 0.1553955078125
▁reduced 1.1416015625
▁side 0.77197265625
▁effects 0.08441162109375
▁compared 2.474609375
▁to 0.11083984375
▁traditional 1.66796875
▁treat 2.3515625
ments 7.355213165283203e-05
. 0.239990234375
▁Initial 5.71484375
▁tri 3.01171875
als 0.0009441375732421875
▁conducted 3.611328125
▁on 1.7099609375
▁a 3.052734375
▁small 0.97314453125
▁sample 2.5703125
▁size 2.083984375
▁indicate 3.494140625
▁that 0.315673828125
▁B 1.1689453125
TX 0.0023365020751953125
- 0.0037555694580078125
1 0.0016927719116210938
2 0.0009446144104003906
3 0.0010137557983398438
▁shows 4.2265625
▁remarkable 4.58984375
▁potential 2.98828125
▁in 1.4814453125
▁in 4.1484375
hib 0.006378173828125
iting 0.004322052001953125
▁the 0.86279296875
▁growth 0.420166015625
▁of 0.1954345703125
▁various 4.35546875
▁types 0.58544921875
▁of 0.005245208740234375
▁cancer 0.1820068359375
▁cells 0.64306640625
, 1.0888671875
▁providing 5.87890625
▁a 1.5869140625
▁g 4.3125
lim 0.1328125
mer 0.0012874603271484375
▁of 0.0018157958984375
▁hope 0.0170745849609375
▁for 0.6171875
▁patients 0.75341796875
▁currently 3.830078125
▁fighting 3.25390625
▁the 1.62890625
▁disease 0.1278076171875
. 0.1300048828125
<0x0A> 0.451171875
Dr 4.62109375
. 0.08984375
▁Emma 7.3046875
▁Davis 6.3671875
, 0.171142578125
▁lead 3.837890625
▁research 0.7109375
er 0.02581787109375
▁at 2.5703125
▁Bi 0.88330078125
ote 0.00208282470703125
ch 0.0195159912109375
▁UK 0.017730712890625
, 0.251708984375
▁expressed 3.2265625
▁c 5.53125
aut 0.0004088878631591797
ious 0.01253509521484375
▁optim 0.035858154296875
ism 9.655952453613281e-05
▁about 1.3740234375
▁the 0.09869384765625
▁pre 5.45703125
lim 0.043182373046875
inary 0.00081634521484375
▁results 0.396240234375
, 1.7734375
▁highlight 5.375
ing 0.002696990966796875
▁that 1.779296875
▁B 2.6796875
TX 0.0014581680297851562
- 0.0027523040771484375
1 0.0015153884887695312
2 0.0008525848388671875
3 0.0011959075927734375
▁has 1.8603515625
▁shown 1.7666015625
▁encourag 4.32421875
ing 0.002788543701171875
▁out 5.8359375
comes 0.0036678314208984375
▁in 0.417236328125
▁vit 4.2734375
ro 0.0018596649169921875
▁and 1.3564453125
▁in 0.1700439453125
▁animal 2.443359375
▁models 0.5615234375
. 0.92138671875
▁However 1.865234375
, 0.003963470458984375
▁she 1.044921875
▁emphas 2.6171875
ized 0.1082763671875
▁the 0.724609375
▁need 0.5966796875
▁for 0.183349609375
▁extensive 3.861328125
▁human 3.7421875
▁tri 0.88134765625
als 0.0001932382583618164
▁to 0.80859375
▁truly 5.09375
▁as 3.798828125
certain 0.00028324127197265625
▁its 1.35546875
▁effect 1.494140625
iveness 0.00328826904296875
▁and 0.9912109375
▁potential 2.9453125
▁side 0.595703125
▁effects 0.0301055908203125
. 0.41748046875
▁Dr 2.69921875
. 0.00893402099609375
▁Davis 0.03204345703125
▁stated 2.6796875
, 0.9130859375
▁" 0.11944580078125
Wh 3.556640625
ile 0.11749267578125
▁we 1.34765625
▁are 0.646484375
▁encourag 0.6455078125
ed 0.00322723388671875
▁by 0.142822265625
▁these 1.8271484375
▁early 1.3544921875
▁find 1.7197265625
ings 9.417533874511719e-06
, 0.136474609375
▁it 2.63671875
▁is 0.2880859375
▁imper 4.14453125
ative 0.0003383159637451172
▁to 1.7060546875
▁conduct 1.3720703125
▁rig 3.974609375
orous 0.01085662841796875
▁clin 1.49609375
ical 0.0008368492126464844
▁tri 0.153564453125
als 1.895427703857422e-05
▁and 3.556640625
▁assess 3.2109375
▁the 0.49072265625
▁drug 1.330078125
' 0.1943359375
s 0.0004229545593261719
▁safety 0.97314453125
▁and 0.339111328125
▁effic 0.255126953125
acy 2.205371856689453e-05
▁in 1.111328125
▁larger 2.8203125
▁patient 1.1708984375
▁populations 0.428955078125
." 1.1611328125
<0x0A> 0.12188720703125
As 3.923828125
▁news 6.51953125
▁of 0.0863037109375
▁this 1.861328125
▁break 2.310546875
through 0.0018205642700195312
▁spread 2.1953125
, 1.5810546875
▁invest 3.146484375
ors 0.0682373046875
▁and 1.94921875
▁medical 1.8740234375
▁profession 0.0924072265625
als 6.210803985595703e-05
▁al 0.265625
ike 1.609325408935547e-05
▁have 1.359375
▁become 5.5546875
▁intr 4.31640625
igu 0.0049896240234375
ed 8.440017700195312e-05
, 3.970703125
▁driving 6.10546875
▁up 1.7529296875
▁the 0.495361328125
▁value 2.380859375
▁of 0.00847625732421875
▁Bi 0.435546875
ote 0.0018472671508789062
ch 0.01531982421875
▁UK 0.08477783203125
▁stock 1.455078125
s 2.1015625
. 0.740234375
▁However 1.7255859375
, 0.004512786865234375
▁industry 1.0458984375
▁anal 0.230224609375
yst 5.805492401123047e-05
s 0.006561279296875
▁are 0.892578125
▁w 4.37890625
ary 0.0004277229309082031
▁of 0.2081298828125
▁prem 4.68359375
ature 0.0016641616821289062
▁ex 5.8046875
uber 0.0238800048828125
ance 0.005462646484375
, 0.76708984375
▁rem 4.67578125
inding 0.006130218505859375
▁st 5.8203125
ake 0.0003514289855957031
hold 0.0019512176513671875
ers 7.271766662597656e-06
▁of 1.8544921875
▁the 0.10125732421875
▁significant 3.638671875
▁challeng 2.16796875
es 8.082389831542969e-05
▁that 1.283203125
▁lie 0.95703125
▁ahead 0.034210205078125
▁in 1.509765625
▁bringing 4.046875
▁B 1.62890625
TX 0.0009112358093261719
- 0.002262115478515625
1 0.0010137557983398438
2 0.00039577484130859375
3 0.00041556358337402344
▁to 0.07720947265625
▁market 0.283447265625
. 0.151123046875
<0x0A> 1.287109375
One 3.806640625
▁of 1.4365234375
▁the 0.173583984375
▁major 2.4140625
▁hur 2.390625
d 5.733966827392578e-05
les 0.00023818016052246094
▁the 3.775390625
▁drug 0.865234375
▁must 1.87890625
▁overcome 0.1280517578125
▁is 0.34619140625
▁the 0.99951171875
▁rig 6.57421875
orous 0.07879638671875
▁testing 1.8291015625
▁and 2.373046875
▁regul 1.7548828125
atory 0.00013136863708496094
▁appro 0.3037109375
val 0.0002446174621582031
▁process 0.22265625
▁for 3.9609375
▁ph 2.884765625
arma 0.00125885009765625
ce 0.0005478858947753906
ut 9.5367431640625e-06
ical 0.0002677440643310547
▁products 1.083984375
. 0.323486328125
▁The 2.544921875
▁drug 2.1953125
▁must 1.14453125
▁pass 1.91015625
▁several 2.884765625
▁stages 2.390625
▁of 0.150146484375
▁clin 1.9697265625
ical 0.0005998611450195312
▁tri 0.268310546875
als 0.0003554821014404297
▁before 1.20703125
▁it 0.79052734375
▁can 0.35302734375
▁be 0.377685546875
▁de 4.3125
emed 0.00026702880859375
▁safe 0.2587890625
▁and 0.1719970703125
▁effective 0.10650634765625
▁for 1.3525390625
▁w 2.37890625
ides 6.0558319091796875e-05
p 0.002655029296875
read 7.963180541992188e-05
▁use 0.1783447265625
. 0.252197265625
▁These 3.13671875
▁tri 0.2239990234375
als 7.033348083496094e-06
▁are 1.931640625
▁essential 5.96875
▁to 0.8017578125
▁determine 3.3671875
▁the 0.798828125
▁drug 0.51220703125
' 0.0010280609130859375
s 7.092952728271484e-05
▁optimal 6.359375
▁dos 0.14892578125
age 0.12445068359375
, 0.6201171875
▁potential 3.228515625
▁side 0.138427734375
▁effects 0.006519317626953125
, 0.09173583984375
▁and 0.0648193359375
▁overall 2.02734375
▁impact 3.986328125
▁on 0.051300048828125
▁different 6.04296875
▁cancer 1.984375
▁types 0.281494140625
. 0.11669921875
▁The 3.533203125
▁length 4.3984375
▁and 1.544921875
▁complexity 0.36865234375
▁of 0.002918243408203125
▁this 2.54296875
▁process 0.1766357421875
, 4.04296875
▁combined 2.171875
▁with 0.00016260147094726562
▁the 0.366943359375
▁possibility 5.7265625
▁of 0.195068359375
▁un 2.3359375
for 0.268310546875
ese 0.00571441650390625
en 0.008392333984375
▁comp 2.3984375
lications 0.0012531280517578125
, 0.2421875
▁pose 3.904296875
▁considerable 4.14453125
▁ris 0.79638671875
ks 3.5762786865234375e-06
▁to 0.484375
▁the 1.4345703125
▁drug 1.6865234375
' 0.11309814453125
s 0.00010526180267333984
▁development 1.90625
. 0.53857421875
<0x0A> 0.1580810546875
F 3.685546875
ur 0.081298828125
ther 4.1961669921875e-05
more 0.387451171875
, 0.00016641616821289062
▁ske 8.9765625
pt 0.7900390625
ics 0.59130859375
▁argue 3.046875
▁that 0.0126953125
▁even 4.421875
▁if 0.1339111328125
▁the 1.0517578125
▁drug 0.12890625
▁passes 1.7724609375
▁all 1.689453125
▁necessary 2.779296875
▁testing 1.9423828125
▁and 1.4951171875
▁appro 2.419921875
val 0.00012505054473876953
▁stages 3.37890625
, 0.0227813720703125
▁the 1.8857421875
▁market 2.9296875
▁for 1.01171875
▁cancer 0.457275390625
▁treatment 2.42578125
▁is 1.14453125
▁highly 1.380859375
▁compet 0.630859375
itive 0.00014972686767578125
▁and 0.6162109375
▁domin 4.921875
ated 0.0004982948303222656
▁by 0.0012674331665039062
▁established 1.396484375
▁ph 1.015625
arma 0.0008091926574707031
ce 0.00421142578125
ut 1.7881393432617188e-06
ical 1.5616416931152344e-05
▁gi 1.33203125
ants 3.2901763916015625e-05
. 0.275390625
▁Bi 3.08984375
ote 0.0010547637939453125
ch 0.11199951171875
▁UK 0.16162109375
▁would 4.45703125
▁have 1.498046875
▁to 0.2470703125
▁navigate 4.82421875
▁a 0.75
▁complex 1.52734375
▁landscape 0.94091796875
▁to 2.34375
▁secure 2.88671875
▁market 2.14453125
▁share 0.55419921875
▁and 1.078125
▁face 6.234375
▁fier 1.6240234375
ce 0.0010347366333007812
▁competition 0.03985595703125
▁from 0.37060546875
▁big 3.919921875
▁industry 5.19140625
▁players 0.487548828125
, 3.353515625
▁some 4.67578125
▁of 0.0192718505859375
▁whom 0.6826171875
▁are 1.572265625
▁invest 4.8828125
ing 0.017913818359375
▁significant 3.67578125
▁resources 0.7158203125
▁in 0.9814453125
▁similar 3.89453125
▁research 2.875
. 1.5595703125
<0x0A> 0.295654296875
Anal 4.3125
yst 0.0011987686157226562
s 0.006542205810546875
▁have 3.232421875
▁also 1.58984375
▁raised 1.404296875
▁concerns 0.1993408203125
▁about 0.28173828125
▁the 0.323486328125
▁potential 1.78125
▁impact 2.48046875
▁on 3.560546875
▁patients 3.4375
▁who 3.2734375
▁might 3.0703125
▁pin 16.53125
▁all 4.6015625
▁their 0.3076171875
▁hopes 0.067626953125
▁on 0.0653076171875
▁a 1.9765625
▁drug 2.447265625
▁that 0.278076171875
▁still 3.9609375
▁has 1.7822265625
▁a 1.212890625
▁long 0.11981201171875
▁path 4.0703125
▁to 0.2049560546875
▁appro 3.015625
val 0.0002065896987915039
. 0.40869140625
▁The 2.572265625
▁emot 8.890625
ional 0.0252227783203125
▁to 1.8798828125
ll 0.0006728172302246094
▁of 0.41357421875
▁dashed 12.53125
▁expect 1.2763671875
ations 1.71661376953125e-05
▁can 2.64453125
▁be 0.446533203125
▁dev 1.2109375
ast 0.0001252889633178711
ating 5.078315734863281e-05
▁for 0.83984375
▁patients 0.44873046875
▁and 0.5869140625
▁their 0.2353515625
▁families 0.52783203125
. 1.5927734375
▁Exper 5.83984375
ts 0.174560546875
▁stress 3.2578125
▁the 0.7548828125
▁importance 0.57568359375
▁of 0.003932952880859375
▁maintain 3.626953125
ing 0.00025725364685058594
▁real 2.5703125
istic 0.09637451171875
▁expect 0.022735595703125
ations 7.510185241699219e-06
▁throughout 3.912109375
▁the 0.09881591796875
▁drug 1.099609375
▁development 0.7021484375
▁process 0.055816650390625
, 0.9375
▁while 2.666015625
▁continu 4.5859375
ing 0.06707763671875
▁to 0.0215301513671875
▁investigate 7.86328125
▁and 3.025390625
▁invest 3.9140625
▁in 0.030853271484375
▁alternative 3.0546875
▁treatment 1.6435546875
▁options 0.10247802734375
. 0.444091796875
<0x0A> 0.11566162109375
Dr 4.7578125
. 0.0146942138671875
▁Am 7.70703125
elia 3.958984375
▁Thompson 5.86328125
, 0.157958984375
▁an 2.248046875
▁on 0.94580078125
colog 0.1295166015625
ist 0.004619598388671875
▁at 0.71044921875
▁a 4.1796875
▁leading 1.3828125
▁cancer 0.943359375
▁center 0.62841796875
, 0.66357421875
▁advis 6.56640625
es 0.0004343986511230469
▁ca 0.2445068359375
ution 4.9233436584472656e-05
▁and 2.2578125
▁p 0.92041015625
atience 0.0193939208984375
. 2.58203125
▁" 1.28515625
Wh 2.31640625
ile 0.006458282470703125
▁the 1.78125
▁initial 2.28515625
▁results 0.60888671875
▁are 0.4248046875
▁indeed 7.171875
▁prom 0.390380859375
ising 0.00011241436004638672
, 0.0792236328125
▁it 1.2705078125
▁is 0.53955078125
▁essential 2.736328125
▁for 2.673828125
▁patients 0.67578125
▁and 0.8251953125
▁the 3.71484375
▁medical 0.72216796875
▁community 0.10797119140625
▁to 0.28564453125
▁exercise 4.3203125
▁rest 4.1484375
raint 0.0006227493286132812
▁until 2.845703125
▁the 1.45703125
▁drug 0.88525390625
' 3.09375
s 0.00015532970428466797
▁safety 1.5791015625
▁and 0.115966796875
▁effic 0.2327880859375
acy 1.33514404296875e-05
▁have 0.7470703125
▁been 0.005672454833984375
▁proven 1.9619140625
▁in 0.76806640625
▁rig 4.5625
orous 0.025665283203125
▁clin 0.410400390625
ical 0.00024580955505371094
▁tri 0.0301513671875
als 1.6689300537109375e-06
," 0.89404296875
▁she 0.7109375
▁emphas 2.982421875
ized 0.5859375
. 0.043182373046875
▁" 0.71484375
There 3.173828125
▁have 4.90625
▁been 0.12103271484375
▁instances 4.64453125
▁in 1.017578125
▁the 0.276123046875
▁past 0.022979736328125
▁where 0.280029296875
▁initial 4.9453125
▁excitement 3.70703125
▁around 3.44140625
▁potential 3.576171875
▁break 1.6572265625
through 0.00016319751739501953
s 0.451904296875
▁has 0.6689453125
▁not 5.45703125
▁been 1.451171875
▁translated 5.03125
▁into 0.097412109375
▁real 2.205078125
- 0.92236328125
world 0.042938232421875
▁success 3.494140625
." 0.77197265625
<0x0A> 0.138916015625
U 4.47265625
lt 0.0555419921875
imately 0.001026153564453125
, 0.001316070556640625
▁Bi 1.8291015625
ote 0.0009026527404785156
ch 0.009002685546875
▁UK 0.01265716552734375
' 1.8994140625
s 0.00031876564025878906
▁B 2.20703125
TX 0.0012960433959960938
- 0.0024509429931640625
1 0.0007882118225097656
2 0.00031685829162597656
3 0.0004372596740722656
▁has 2.76171875
▁shown 2.529296875
▁great 2.064453125
▁promise 0.1680908203125
▁in 0.50439453125
▁the 1.330078125
▁early 0.7802734375
▁stages 0.0751953125
▁of 0.042144775390625
▁testing 0.70947265625
, 0.9736328125
▁offering 2.482421875
▁a 1.744140625
▁g 0.57177734375
lim 0.094482421875
mer 0.00012040138244628906
▁of 0.0009775161743164062
▁hope 0.0100250244140625
▁for 0.67431640625
▁cancer 1.5126953125
▁patients 0.0243682861328125
▁eager 8.96875
ly 1.8291015625
▁await 0.0626220703125
ing 0.0018911361694335938
▁new 2.31640625
▁treatment 0.64453125
▁options 0.019439697265625
. 0.0202178955078125
▁However 0.728515625
, 0.00067901611328125
▁careful 5.78125
▁consideration 1.2041015625
▁must 1.99609375
▁be 0.00861358642578125
▁given 0.1695556640625
▁to 0.0196380615234375
▁the 0.30419921875
▁need 7.52734375
▁for 0.06866455078125
▁extensive 1.3603515625
▁clin 0.9873046875
ical 0.00014591217041015625
▁tri 0.036285400390625
als 1.3470649719238281e-05
, 2.71875
▁regul 4.31640625
atory 0.0003154277801513672
▁appro 0.05072021484375
val 4.839897155761719e-05
, 0.29443359375
▁and 0.027374267578125
▁the 2.892578125
▁challeng 4.61328125
es 0.048065185546875
▁pos 3.64453125
ed 0.00014209747314453125
▁by 0.006595611572265625
▁the 0.437744140625
▁compet 1.7880859375
itive 0.0018949508666992188
▁market 1.4833984375
. 2.08203125
▁While 3.0703125
▁the 1.205078125
▁road 5.61328125
▁ahead 0.3603515625
▁remains 1.765625
▁uncertain 1.1806640625
, 0.0304718017578125
▁this 4.91015625
▁break 1.5107421875
through 0.0005922317504882812
▁represents 3.12109375
▁a 0.857421875
▁significant 1.8203125
▁step 0.58251953125
▁forward 0.3974609375
▁in 0.5634765625
▁the 0.285400390625
▁fight 0.47412109375
▁against 0.021240234375
▁cancer 0.01554107666015625
▁and 2.712890625
▁provides 3.30078125
▁a 1.71484375
▁be 5.34375
acon 0.00079345703125
▁of 0.00971221923828125
▁hope 0.0404052734375
▁for 0.1473388671875
▁better 10.4921875
▁treatment 0.95849609375
▁options 0.1707763671875
▁in 0.47998046875
▁the 0.01491546630859375
▁future 0.13623046875
. 0.005245208740234375
